Clinical trials: Renal Transplant Recipients
Brain Death, Organ Donation
Deceased Organ Donor Interventions to Protect Kidney Graft Function
To protect kidney function during the transplantation process by comparing mild hypothermia in the deceased organ donor before organs are recovered and pulsatile perfusion of the kidney after recovery and prior to transplantation.
- Conditions
- Brain Death, Organ Donation, Organ Transplant Failure or Rejection, Delayed Graft Function
- Trial name
- NCT02525510
- Testing
- Pump Eligible - Normothermia - Pump Both Kidneys, Pump Eligible - Hypothermia and Pump Right Kidney, Pump Eligible - Hypothermia and Pump Left Kidney
- Where
- 7 sites in United States
- Volunteers
- 1,427 people
- Sponsor
- University of California, San Francisco
Blood Pressure Control, Kidney Transplant Recipient
Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients
The purpose of this study is to identify and manage factors related to blood pressure control that impact organ function and survival in kidney transplant recipients.
- Trial name
- NCT01093703
- Testing
- Medication Adjustment
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Mayo Clinic
Cytomegalovirus, Organ Transplant
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver…
- Conditions
- Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications
- Trial name
- SHIELD (NCT06958796)
- Testing
- Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Camille N. Kotton, MD
Hyperglycaemia, Kidney Transplantation
Continuous Glucose Monitoring (CGM) After Kidney Transplantation
This study examines glucose levels measured by continuous glucose monitoring (CGM) in the immediate period following kidney transplantation among recipients with diabetes, without diabetes, and with pre-diabetes.
- Trial name
- CGM-KTx (NCT06675903)
- Where
- Denmark
- Volunteers
- 54 people
- Sponsor
- Bo Feldt-Rasmussen
Disorder of Transplanted Kidney
Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival
This study will evaluate the association between n-3 polyunsaturated fatty acids and patient and graft survival. The association between other fatty acids and mortality and graft loss endpoints will also be evaluated.
- Trial name
- NCT02017990
- Where
- Norway
- Volunteers
- 2,002 people
- Sponsor
- Oslo University Hospital
BK Virus Nephropathy After Kidney Transplantation
Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.
BK virus nephropathy (BKVN), a consequence of the strong immunosuppressive therapy given after kidney transplantation, represents a growing problem in the kidney transplant (KT) setting.
- Trial name
- BK EVER (NCT03216967)
- Testing
- everolimus
- Where
- 15 sites in France
- Volunteers
- 130 people
- Sponsor
- University Hospital, Strasbourg, France
Renal Insufficiency
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.
- Trial name
- ATG_HVH (NCT01453218)
- Testing
- ATeGe-Fresenius
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Vall d'Hebron
Kidney Failure, Hepatitis C
HCV + to HCV - Kidney Transplant
This is a single center study characterizing the experience of administration of 8 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor…
- Trial name
- NCT04320290
- Testing
- Direct Acting Antivirals
- Sponsor
- Massachusetts General Hospital
Kidney Failure, Graft vs Host Disease
Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus
Compare kidney function as measured by calculated creatinine clearance (using the method by Nankivell)1 at 12 months after transplantation in subjects receiving induction therapy with cyclosporine microemulsion (CsA) and Rapamune…
- Trial name
- NCT00195468
- Testing
- CYCLOSPORINE
- Where
- 13 sites in Brazil, Mexico
- Volunteers
- 280 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Post Transplantation Diabetes Mellitus, Obesity
Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients
Post-transplantation diabetes mellitus (PTDM) is a common medical complication after kidney transplantation, related to both transplant-specific and generic risk factors, and is associated with major complications after…
- Conditions
- Post Transplantation Diabetes Mellitus, Obesity, Transplantation of Kidney
- Trial name
- CAVIAR (NCT02233491)
- Testing
- Active lifestyle intervention, Control
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Covid19, Kidney Transplant Infection
Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients
An open-label, 56 day, single-center, exploratory, proof-of-concept study of the anti-viral effect of voclosporin (VCS) with an extended safety follow-up, up to 1 year.
- Trial name
- VOCOVID (NCT04701528)
- Testing
- Voclosporin, Tacrolimus
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
Kidney Transplant Recipients
Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients
Acumulating data suggest that thrapeutic drug therapeutic may optimize efficacity and tolerance of MMF. It could guarantee better exposure to the drug in the first 3 months and then minimize side effects in the long term.
- Trial name
- NCT00199667
- Testing
- Mycophenolate Mofetil
- Where
- 11 sites in France
- Volunteers
- 137 people
- Sponsor
- University Hospital, Limoges
Delayed Graft Function
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor…
- Trial name
- NCT02474667
- Testing
- ANG-3777
- Where
- 30 sites in United States
- Volunteers
- 253 people
- Sponsor
- Angion Biomedica Corp
CYCLOSPORINE/TACROLIMUS
The Effects of Conversion From Cyclosporine to Tacrolimus on the Changes of Cardiovascular Risk Profiles and Serum Metabolites in Renal Transplant Recipients
The purpose of this study is to evaluate the effects of conversion from cyclosporine to tacrolimus on the changes of cardiovascular risk profiles and serum metabolites in renal transplant recipients.
- Trial name
- NCT02496494
- Testing
- Tacrolimus
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Kyungpook National University Hospital
CMV Specific Immune Response, Kidney Transplant
Risk Factors Associated With the Absence of CMV-specific Cellular Immune Response in the Early Post-transplant Period in Low-risk CMV-seropositive Kidney Transplant Recipients
The goal of this observational study is to identify risk factors associated with the absence of CMV-specific cellular immune response in low-risk CMV-seropositive kidney transplant recipients in the early post-transplant period.
- Conditions
- CMV Specific Immune Response, Kidney Transplant, Kidney Transplant Recipient, CMV Reactivation
- Trial name
- PREDICOR (NCT07621835)
- Where
- Spain
- Volunteers
- 236 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Kidney Diseases
A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients
Comparison between Campath induction and monotherapy with Tacrolimus vs Thymoglobulin induction and triple drug maintenance using Tacrolimus, mycophenolate, and steroids.
- Trial name
- NCT00407160
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Highly Sensitized Prospective Kidney Transplant Recipients
Daratumumab and Belatacept for Desensitization
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors.
- Trial name
- ATTAIN (NCT04827979)
- Testing
- daratumumab, belatacept, Bone marrow aspiration
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant; Complications, Dialysis; Complications
Structured Program of Exercise for Recipients of Kidney Transplantation
Older patients with end- stage kidney disease (ESKD) are at very high risk for functional impairment. Kidney transplantation (KT) has the potential to ameliorate the detrimental effects of ESKD on physical activity and functional…
- Conditions
- Kidney Transplant; Complications, Dialysis; Complications, Physical Disability, Frailty Syndrome
- Trial name
- SPaRKT (NCT04954690)
- Testing
- Structured Program of exercise for Recipients of Kidney Transplantation (WC), Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG), Usual Care
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- University of California, San Francisco
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid…
- Trial name
- NCT01544491
- Testing
- RAD001, MMF
- Where
- 31 sites in United States, Argentina and 11 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
Advances in renal transplantation have increased life-expectancy in patients with end-stage kidney disease. Conventional immunosuppressive drugs prevent efficiently early allograft losses due to T-cell mediated rejection.
- Trial name
- TAMARCIN (NCT02113891)
- Testing
- Eculizumab
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.